Nav1.7

FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company’s novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product. “We are leveraging our existing know-how and intellectual property to target different pain indications and methods of delivery in an efficient and synergistic manner. We are taking advantage of the extensive pre-clinical and Phase I studies performed with CC8464 demonstrating strong efficacy in a wide variety of preclinical models and no dose limiting tolerability concerns in four Phase I trials,” said Frank Knuettel, Chief Executive Officer. Eric Lang, Chief Medical Officer further commented, “Of the various sodium channel targets, NaV1.7 is the most genetically validated for the treatment of pain. The over expression of NaV1.7 activity leads to Erythromelalgia, one of the most severe types of pain described in humans, whereas over expression of NaV1.8 leads to mild-moderate pain. We anticipate that our injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain could be an excellent and potent analgesic.” The Company believes there are strong synergies between the programs and is building a suite of related products to address multiple different types of pain and methods of delivery, with a drug that has shown no addictive properties in 4 Phase I trials. With these programs, the Company hopes to reduce usage of opioids and other sub-optimal drugs in various indications and expects to be able to take advantage of certain NOPAIN Act provisions if the drugs are approved by the FDA. About Chromocell Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and acute and chronic eye pain. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media. Forward-Looking Statements This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the amount of shares of Common Stock to be repurchased under the Repurchase Plan, if any, (ii) the Company’s belief that its Common Stock is undervalued, (iii) the Company’s belief that its Common Stock is an attractive investment at its current price, (iv) the Company’s ability to conduct repurchases in accordance with applicable laws and regulations, (v) our ability to enhance stockholder value and (vi) the impact of laws and regulations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law. For Investor Inquiries:Mike MoyerManaging Director, LifeSci Advisors, LLCmmoyer@lifesciadvisors.com

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized an amendment (the “Amendment”) to the Company’s existing stock repurchase plan (as amended, the “Repurchase Plan”) to increase the total value of shares of Chromocell’s common stock (“Common Stock”) available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000. In addition, the Amendment extends the termination date of the Repurchase Plan from December 31, 2024 to June 30, 2025. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time. “The increased ability to repurchase up to another $500,000 in shares of Chromocell’s common stock – in addition to the $250,000 previously available for repurchase under the repurchase plan – is the result of our continued belief that our common stock is undervalued, and we consider our common stock an attractive investment at the current price,” said Frank Knuettel, Chief Executive Officer and President. Under the Repurchase Plan, the Company may repurchase shares of Common Stock from time to time in open market transactions or in privately negotiated transactions as permitted under the applicable rules and regulations. Open market purchases are intended to be conducted in accordance with the limitations set forth in Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and applicable legal requirements. The timing, volume and nature of such purchases will be determined at the sole discretion of the Company’s management at prices the Company considers attractive and in the best interests of the Company and its stockholders, subject to the availability of stock, general market conditions, trading price, alternate uses for capital, the Company’s financial performance, and applicable securities laws. No assurance can be given that any particular amount of Common Stock will be repurchased. All or some portion of the repurchases will be made pursuant to trading plans under Rule 10b5-1 under the Exchange Act, which will permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. About Chromocell Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and acute and chronic eye pain. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media. Forward-Looking Statements This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the amount of shares of Common Stock to be repurchased under the Repurchase Plan, if any, (ii) the Company’s belief that its Common Stock is undervalued, (iii) the Company’s belief that its Common Stock is an attractive investment at its current price, (iv) the Company’s ability to conduct repurchases in accordance with applicable laws and regulations, (v) our ability to enhance stockholder value and (vi) the impact of laws and regulations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law. Chromocell Media and Investor Inquires: LR Advisors LLCJason Assad678-570-6791Jason@Chromocell.com

Key points: Wearable AF monitoring devices are extensively used in routine practice worldwide. The FDA has agreed on the use of AF monitoring devices in clinical trials for budiodarone approval. The FDA has also issued guidance on the steps required to incorporate wearable AF monitoring devices into a drug label. LOS ALTOS, Calif., Oct. 16, 2024 /PRNewswire/ -- XYRA LLC, a private biopharmaceutical company, is committed to developing innovative therapies for cardiac rhythm disorders with high unmet needs. With the widespread use of FDA-approved wearable Atrial Fibrillation (AF) monitoring devices for arrhythmia detection, it is now possible to identify subjects with long episodes of AF (LEAF) and symptoms; these patients are at high risk of complications including stroke, heart failure and progression to permanent AF. Phase 2 clinical data substantiates that XYRA's drug candidate, budiodarone, delivers significant reductions in symptoms, as well as the frequency and duration of AF episodes, among subjects with non-permanent AF which compare favorably to the results obtained with AF-ablation in a recent study. Upon reaching an agreement with the FDA regarding clinical trial endpoints and potential approval pathway for multiple active doses of budiodarone in the management of non-permanent AF, XYRA sought and received guidance from the FDA on a prospective label for budiodarone use post-approval. The FDA's guidance specified indications and directions for use to control AF symptoms and achieve a safe harbor for stroke risk reduction by elimination of LEAF greater than 5 hours. Both endpoints were demonstrated in Phase 2 trials of budiodarone. The FDA indicated that the label likely would include directions for maintaining patients on the appropriate therapeutic dose of budiodarone. In addition, XYRA's unique approach incorporates AF monitoring and enables the identification of patients who do not respond to the maximum therapeutic dose. This early detection allows for the timely discontinuation of budiodarone in non-responsive patients, thereby preventing unnecessary exposure to a non-therapeutic drug. The FDA indicated that a label for budiodarone including an AF monitoring device requirement is possible if upcoming clinical trials demonstrate that AF montoring systems are able to generate data that could be used to successfully adjust the dosage of budiodarone during treatment. "Xyra assured the Agency that if the proposed label includes a requirement for intermittent AF monitoring with approved wearable devices, only eligible subjects will be prescribed Budiodarone. These patients will be established on the lowest, most effective dose to ensure that symptoms and LEAF are controlled and if there is an inadequate response to the highest recommended dose, treatment will be discontinued," said Peter Milner, M.D., FACC, managing member of XYRA. He added, "Budiodarone, with its dose-proportional pharmacology and intermediate half-life offers an ideal opportunity to integrate state-of-the-art digital AF monitoring technology into routine practice, enabling us to identify the patients with AF who benefit most from the drug. We know the odds of having a stroke with AF goes up 5-fold in the 5 days after a LEAF greater than 5.5 hours. So now that it is possible to identify these patients with wearable AF monitoring devices in real time, it makes sense to treat them with budiodarone and monitor the response to therapy to prevent long episodes of AF from happening again." The currently FDA-approved wearable devices available for use in AF and potentially with budiodarone to determine eligibility and response to therapy include patch devices such as Philips' E-patch® or MCOT®, iRhythm's Zio® Patch, and wrist wearables like the Zio® ZEUS and Apple Watch®. This list is expected to rapidly expand thanks to the phenomenal innovation occurring in the digital healthcare sector such that wearable cardiac monitoring is projected by some to be a $4B business globally by 2028. About Budiodarone: Budiodarone, a Phase 3 enabled, potentially best-in-class mixed ion channel blocker, features esterase metabolism and thus a significantly shorter half-life than amiodarone, with no evidence of accumulation in human or animal studies to date. Its superior efficacy is attributed to its enhanced late sodium channel blocking properties. Budiodarone has demonstrated the ability to treat AF by controlling symptoms, eliminating LEAF, reducing AF burden, and maintaining normal sinus rhythm. About Atrial Fibrillation: Atrial Fibrillation (AF) is the most common sustained heart arrhythmia in adults, affecting approximately 44 million individuals worldwide. It is associated with thromboembolic risk, impaired cardiac performance, and other morbidities. Besides patients with symptomatic AF, the condition is often first detected after a stroke, the development of left ventricular dysfunction, or incidentally via patient examination. The management of AF has evolved over time. Due to accumulating evidence of improved outcomes, previous strategies focusing on simple ventricular rate control have shifted to current therapies that seek to restore and maintain sinus rhythm. AF may be treated with anti-arrhythmic drugs (AAD), electrophysiological ablation, or a combination of both. About XYRA LLC: XYRA LLC is a private biopharmaceutical company committed to developing innovative therapies for cardiac rhythm disorders with high unmet needs. The company's goal is to make AF management comparable to that of other common cardiac conditions, such as hypertension and hypercholesterolemia. In these conditions, upward dose titration of effective drugs, guided by simple and widely available monitoring tools to confirm compliance and response to therapy, has consistently improved outcomes. For information: Investor Relations Contact: [email protected] Logo - SOURCE XYRA WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED